List of Excipients in Branded Drug AURYXIA

Auryxia Excipient Strategy and Commercial Opportunities in Ferric Citrate Tablets

Last updated: August 26, 2026

Auryxia is a ferric citrate tablet marketed by Akebia Therapeutics for hyperphosphatemia in adults with chronic kidney disease on dialysis and for iron deficiency anemia in adults with chronic kidney disease not on dialysis. Its commercial opportunity is driven by a relatively simple immediate-release tablet platform, high chronic prescription volume, and the possibility of lower-cost generic or authorized-generic manufacturing. The main excipient priorities are tablet robustness, rapid and reproducible dissolution, iron-related stability, color control, swallowability, and manufacturing economics.

What is Auryxia and how does its formulation work?

Auryxia contains ferric citrate as the active ingredient. Each 1-gram tablet contains 210 mg of elemental iron. The drug acts locally in the gastrointestinal tract by binding dietary phosphate. In patients with iron deficiency anemia, some iron is absorbed systemically.

Product attribute	Auryxia profile
Active ingredient	Ferric citrate
Strength	1,000 mg ferric citrate per tablet
Elemental iron	210 mg per tablet
Dosage form	Oral immediate-release film-coated tablet
Initial FDA approval	2014
Initial indication	Hyperphosphatemia in adults with CKD on dialysis
Expanded indication	Iron deficiency anemia in adults with CKD not on dialysis
NDA	205874
U.S. commercial holder	Akebia Therapeutics
Primary administration issue	Tablets are taken with meals and titrated to serum phosphate response

The label identifies inactive ingredients that include microcrystalline cellulose, sodium starch glycolate, hypromellose, titanium dioxide, triacetin, and FD&C Yellow No. 6 aluminum lake.[1]

The formulation is commercially important because ferric citrate is both the active pharmaceutical ingredient and the source of the tablet's high mass. Excipients therefore must support manufacturability without materially increasing tablet size or weakening the ferric citrate payload.

What excipients are used in Auryxia tablets?

The core Auryxia excipient system is consistent with a conventional immediate-release, film-coated tablet.

Excipient	Likely formulation function
Microcrystalline cellulose	Diluent, compression aid, tablet structure
Sodium starch glycolate	Superdisintegrant for rapid breakup
Hypromellose	Film-coating polymer and surface protection
Titanium dioxide	Opacifier and color-control agent
Triacetin	Plasticizer for the film coating
FD&C Yellow No. 6 aluminum lake	Tablet colorant
Film-coating system	Swallowability, identification, handling, and appearance

Microcrystalline cellulose is strategically important because ferric citrate has a high active load. The diluent must provide sufficient compactibility while avoiding excessive tablet weight. Sodium starch glycolate is important because the product must disintegrate despite the dense inorganic active ingredient.

The coating system has commercial value beyond appearance. A film coat can reduce friability, improve tablet handling, limit direct contact with the iron-containing core, and improve patient acceptance. Color consistency also supports product identification in a population taking multiple phosphate binders and renal medicines.

How does ferric citrate affect excipient selection?

Ferric citrate creates several formulation constraints.

High active load

A 1-gram tablet contains a large amount of ferric citrate. Conventional excipients cannot compensate for poor powder flow or weak compaction without increasing tablet dimensions. Direct-compression excipients with high compactibility are therefore commercially attractive.

Potential formulation approaches include:

• High-functionality microcrystalline cellulose.
• Co-processed cellulose and disintegrant systems.
• Spray-dried or granulated excipient blends.
• Low-level glidants and lubricants designed to preserve dissolution.
• High-solids film coatings that limit weight gain.

Chemical and physical stability

Iron-containing materials can create risks involving discoloration, oxidation-sensitive excipients, moisture uptake, and interaction with packaging components. Excipient suppliers can compete by offering low-moisture, low-peroxide, and narrow-specification materials.

Relevant development controls include:

• Water activity and residual moisture.
• Excipient peroxide levels.
• Tablet color drift.
• Dissolution after accelerated stability storage.
• Hardness and friability over shelf life.
• Extractables and leachables from bottles and liners.

Ferric citrate is also sensitive to the broader chemical environment of the tablet. An excipient that performs well in a neutral small-molecule formulation may cause unacceptable color or dissolution changes in an iron-containing tablet.

Dissolution and disintegration

A generic Auryxia formulation must replicate the relevant product performance rather than simply match the inactive-ingredient list. A formulation with excessive compression force, hydrophobic lubrication, or inadequate disintegrant distribution may produce slower dissolution.

This creates an opportunity for excipient manufacturers that can demonstrate:

• Consistent liquid uptake.
• Rapid tablet breakup at high compression force.
• Low lubricant sensitivity.
• Consistent performance across commercial-scale presses.
• Comparable dissolution under multiple pH conditions.

What formulation patents protect Auryxia?

Auryxia's intellectual-property position has historically included patents directed to ferric citrate compositions, pharmaceutical preparations, and methods of treating hyperphosphatemia or iron deficiency anemia. The relevant protection is not limited to the inactive-ingredient list in the FDA label.

Protection category	Commercial relevance
Ferric citrate composition claims	Can cover the active material or specified ferric citrate preparations
Tablet or pharmaceutical composition claims	May cover active-to-excipient combinations or physical attributes
Method-of-use claims	Can delay or complicate generic commercialization for specific indications
Manufacturing claims	May cover preparation, processing, or control of ferric citrate
Orange Book-listed patents	Must be addressed in an ANDA certification or a Section VIII statement, depending on claim scope

Publicly reported Auryxia-related patent families include U.S. Patent Nos. 8,609,896, 8,895,756, 9,114,111, 10,857,205, and later continuation or related patents. Expiration timing depends on patent family, terminal disclaimers, patent-term adjustment, and any applicable regulatory extension. Several core families have been reported with nominal terms extending into the late 2020s or early 2030s.[2][3]

The commercial implication is direct: an excipient redesign does not necessarily avoid patent risk. A generic developer can replace every inactive ingredient and still face composition, manufacturing, or method-of-use claims covering the active product.

What is the Orange Book status of Auryxia?

Auryxia is an FDA-approved small-molecule drug listed under NDA 205874. Its relevant exclusivity analysis is therefore based on small-molecule regulatory rules, Orange Book patent listings, ANDA certifications, and any settlement restrictions. Biosimilar rules do not apply.

Regulatory issue	Auryxia implication
FDA pathway	ANDA for a conventional generic tablet
Reference product	Auryxia tablets
Biosimilar pathway	Not applicable
Patent certifications	Paragraph I, II, III, IV, or Section VIII, depending on listed claims
Exclusivity	Must be assessed separately from patent expiry
Formulation substitution	Requires demonstration of pharmaceutical equivalence and bioequivalence
Label carve-out	Potentially relevant for patented methods of use

The FDA Orange Book is the controlling source for currently listed patents and exclusivity codes. Patent families may continue through continuations even after an earlier patent expires. A commercial launch assessment must therefore distinguish between:

1. The earliest legally permissible launch date.
2. The expiration of each listed patent.
3. Any 30-month stay from Paragraph IV litigation.
4. Settlement-based launch restrictions.
5. The scope of the generic label and any carve-outs.

Which companies are challenging Auryxia exclusivity?

Auryxia has attracted generic interest because it is a chronic-use renal product with a tablet dosage form and no biosimilar manufacturing barrier. Public litigation records have identified ANDA-related disputes involving generic manufacturers including Amneal, Teva, and Zydus, among others.[4]

Paragraph IV litigation risk centers on whether the accused generic product infringes ferric citrate composition, formulation, process, or method-of-use claims. A generic company may challenge validity, enforceability, or infringement. It may also pursue a Section VIII carve-out for a patented indication while retaining an unprotected indication.

Settlement agreements can establish an agreed generic launch date, but the terms may be confidential or disclosed only in court filings, regulatory submissions, or antitrust reporting. The relevant commercial question is not simply whether a Paragraph IV filing occurred. It is whether the challenge resulted in:

• A judgment of invalidity or noninfringement.
• A settlement with an authorized launch date.
• A licensed launch.
• A dismissal.
• A continuing dispute over later-issued continuation patents.

When does Auryxia lose exclusivity?

Auryxia's regulatory exclusivity and patent protection should be modeled separately.

The product received FDA approval in 2014, while the anemia indication was added in 2017.[1] New indication approval can create regulatory exclusivity in some circumstances, but it does not automatically reset the full patent term for the product. Core patent protection has been reported to extend beyond the initial seven-year orphan-drug exclusivity period associated with the hyperphosphatemia indication.[2]

A practical launch timeline should use these checkpoints:

Timeline event	Effect on competition
2014 initial approval	Established the reference product
2017 anemia indication	Expanded market and created method-of-use considerations
Patent expiry in late 2020s or early 2030s	Depends on the specific listed patent and applicable adjustments
ANDA approval	Does not necessarily permit launch if a stay or settlement applies
First generic entry	Typically creates rapid price and share pressure
Multiple generic entry	Increases rebate and distribution competition

The most important risk is a staggered launch. One generic may enter under a licensed settlement while a later continuation patent remains enforceable against other products. That scenario can preserve partial branded protection while still reducing net price.

What commercial opportunities exist for excipient suppliers?

The strongest opportunity is not an entirely new excipient. It is a higher-performance excipient package that reduces manufacturing cost or development risk.

Direct-compression platforms

Auryxia's high active load creates demand for excipient blends that improve powder flow and compactibility. A supplier that can support robust tablet production at lower compression force may reduce press wear, weight variability, and rejected batches.

Commercial targets include:

• Co-processed microcrystalline cellulose systems.
• Direct-compression grades with controlled particle-size distributions.
• Low-moisture grades for iron-containing formulations.
• Disintegrant blends that work at low concentration.
• Lubricant-tolerant systems.

Color and coating alternatives

The current formulation uses titanium dioxide and FD&C Yellow No. 6 aluminum lake. Regulatory or customer preferences may create demand for alternative color systems, including colorant-free or iron-compatible coatings.

Opportunities include:

• Titanium-dioxide-free coating systems.
• Stable yellow or amber shades without aluminum lakes.
• Lower-weight coatings that maintain tablet protection.
• Pigment systems with reduced batch-to-batch variation.
• Coatings that improve swallowability without delaying disintegration.

A color change can trigger comparability, stability, and regulatory work. It may be easier for a generic developer to use the reference appearance than to introduce a differentiated color system unless the new coating solves a clear manufacturing or market problem.

Packaging and moisture control

High-volume dialysis and nephrology products can benefit from packaging that controls moisture and limits tablet discoloration. Commercial opportunities include:

• High-barrier HDPE bottles.
• Induction seals with improved moisture performance.
• Desiccant-integrated closures.
• Unit-dose blister systems for adherence and dispensing.
• Packaging optimized for pharmacy automation.

Packaging is particularly relevant where an excipient redesign changes moisture sensitivity. A cheaper tablet may require a more expensive container, eliminating the expected savings.

How strong is the Auryxia formulation patent estate?

The estate is stronger at the active-ingredient and therapeutic-use level than at the basic excipient level, based on publicly reported patent categories. A simple substitution of microcrystalline cellulose, coating polymer, or colorant may reduce formulation overlap but does not eliminate infringement risk.

Risk area	Relative commercial risk
Active ferric citrate composition	High
Indication-specific method claims	Medium to high
Core tablet formulation	Medium
Exact inactive-ingredient replication	Medium
Alternative coating color	Low to medium
Manufacturing process	Product-specific
Excipient supplier IP	Usually secondary to drug-owner IP

An excipient supplier should avoid relying on the premise that the label's inactive ingredients are unprotected. FDA labeling identifies composition but does not determine patent scope. Patent claims are interpreted from the issued claims, specification, prosecution history, and relevant court decisions.

How does Auryxia compare with competing phosphate binders?

Auryxia competes with calcium-based binders, sevelamer, lanthanum carbonate, sucroferric oxyhydroxide, and other phosphate-binding products.

Product class	Excipient and manufacturing implication
Ferric citrate	High active tablet mass; iron-related stability and color control
Sevelamer	Polymer-based product with different swelling and dissolution behavior
Sucroferric oxyhydroxide	Chewable tablet platform and complex inorganic active
Lanthanum carbonate	Chewable formulations with taste and texture priorities
Calcium acetate	Low-cost, relatively simple tablet or capsule manufacturing
Non-calcium binders	Higher-value formulations but often more complex excipient systems

Auryxia's differentiation is the combined phosphate-binding and iron-delivery profile. For generic competition, that benefit also creates a technical challenge: the tablet must reproduce the reference product's pharmaceutical performance while managing elemental iron exposure and tolerability.

What generic launch risks exist for Auryxia?

Generic launch risk is commercially meaningful because the product is administered chronically and is not dependent on a biologic manufacturing platform. The main barriers are legal and bioequivalence execution rather than complex sterile production.

Key risks include:

• Paragraph IV litigation and a potential 30-month stay.
• Continuation patents issued after the initial ANDA filing.
• Method-of-use claims covering one indication.
• Difficulty demonstrating comparable dissolution for a high-load inorganic tablet.
• Product discoloration or stability failures.
• Manufacturing scale-up problems involving flow, sticking, or weight variation.
• Physician and dialysis-center switching controls.
• Payer preference for lower-cost phosphate binders.
• Patient adherence effects from tablet size and dosing frequency.

The most commercially credible generic strategy is usually a conservative formulation that matches the reference product's appearance, dosage form, dissolution profile, and label scope. Excipient innovation has value when it lowers cost or improves stability without creating new regulatory or patent complexity.

What licensing and partnership opportunities exist?

Auryxia's most practical partnership opportunities are upstream and manufacturing-focused:

1. Co-development with a direct-compression excipient supplier.
2. Contract manufacturing using validated high-load tablet technology.
3. Regional licensing where Auryxia patent coverage differs by jurisdiction.
4. Authorized-generic supply arrangements.
5. Packaging partnerships for unit-dose renal-care distribution.
6. Reformulation partnerships targeting smaller tablets or improved swallowability.

Publicly identified commercial control of the U.S. product rests with Akebia following its combination with Keryx.[5] No excipient-specific licensing arrangement is established in the sources cited here. International rights, local registrations, and regional patent positions should be analyzed separately because ferric citrate products and phosphate-binder markets vary substantially by jurisdiction.

Key Takeaways

• Auryxia is a high-load ferric citrate immediate-release tablet with a conventional but technically demanding excipient platform.
• Microcrystalline cellulose and sodium starch glycolate are central to tablet manufacturability and dissolution.
• Iron-related moisture, discoloration, and stability issues create opportunities for specialized excipient and coating suppliers.
• The most attractive excipient opportunity is a co-processed direct-compression system that improves flow, hardness, disintegration, and cost.
• Auryxia is a small molecule, so biosimilar competition is irrelevant; ANDA-based generic competition is the principal threat.
• Patent risk extends beyond the inactive-ingredient list and includes ferric citrate compositions, methods of use, formulations, and manufacturing claims.
• Commercial success for a generic depends on coordinated excipient selection, dissolution control, patent strategy, label design, and scale-up execution.

FAQs About Auryxia Excipient Strategy and Market Entry

Can a generic Auryxia use different excipients?

Yes. An ANDA generally does not require an identical inactive-ingredient system, but the proposed product must satisfy pharmaceutical-equivalence, bioequivalence, quality, stability, and labeling requirements. Different excipients can also create formulation-patent or litigation issues.

Is Auryxia a biologic or does it face biosimilar competition?

No. Auryxia contains ferric citrate, a small-molecule active ingredient. Competition would proceed primarily through an ANDA or another small-molecule pathway, not the biosimilar pathway.

Which excipient is most important for a generic Auryxia tablet?

Microcrystalline cellulose is likely the most important structural excipient because of the tablet's high ferric citrate load. Sodium starch glycolate is also critical for maintaining rapid disintegration.

Could a colorant-free Auryxia formulation create a commercial advantage?

Potentially. A colorant-free tablet could address customer preferences and reduce pigment-related variability, but it would need to preserve identification, stability, appearance, and regulatory comparability.

Does changing the coating avoid Auryxia patents?

Not necessarily. A coating change may avoid a narrow formulation claim, but patents covering ferric citrate composition, manufacturing, or methods of use can remain relevant.

References

1. U.S. Food and Drug Administration. (2024). Auryxia (ferric citrate) prescribing information.
2. U.S. Patent and Trademark Office. (n.d.). Patent Center records for ferric citrate composition, formulation, and method-of-use patent families.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. PACER. (n.d.). Federal district court records involving Auryxia, Keryx Biopharmaceuticals, Akebia Therapeutics, and ANDA applicants.
5. Akebia Therapeutics, Inc. (2024). Annual report on Form 10-K.